JANX Stock Analysis: Buy, Sell, or Hold?
JANX - Janux Therapeutics, Inc. Common Stock
$13.59
-0.19 (-1.38%)
▼
5d:
-5.89%
30d:
-5.76%
90d:
-5.3%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When JANX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JANX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: JANX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: JANX is currently trading at $13.59, which is considered oversold relative to its 30-day fair value range of $14.02 to $14.67.
Technical Outlook: Technically, JANX is in a uptrend. The price is currently testing key support at $13.51. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: JANX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $40.56 (+198.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JANX is in a uptrend. The price is currently testing key support at $13.51. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: JANX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $40.56 (+198.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.02 -
$14.67
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 198.5% below Wall St target ($40.56)
- CAUTION: Recommendation downgraded due to -5.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$14.02 -
$14.67
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.04
(7.6%)
Support & Resistance Levels
Support Level
$13.51
Resistance Level
$14.87
Current Trend
Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.90
Wall Street Target
$40.56
(+198.5%)
Revenue Growth (YoY)
2177.9%
Share & Embed Analysis
Last updated: June 03, 2026 5:58 PM ET
Data refreshes hourly during market hours. Next update: 6:58 PM
Data refreshes hourly during market hours. Next update: 6:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JANX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrew Hollman Meyer
SELL
1879 shares
2026-01-02
Charles M Winter
SELL
2401 shares
2026-01-02
David Alan Campbell
SELL
8072 shares
2026-01-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 54 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 59 HOLD |
